<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>402</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12662928</PubmedId>
            <Abstract>The alpha1beta1 (VLA-1) integrin is a cell-surface receptor for collagen and laminin and has been implicated in biological pathways involved in several pathological processes. These processes may be inhibited by the monoclonal antibody AQC2, which binds with high affinity to human alpha1beta1 integrin. To understand the structural basis of the inhibition we determined the crystal structure of the complex of a chimeric rat/human I domain of the alpha1beta1 integrin and the Fab fragment of humanized AQC2 antibody. The structure of the complex shows that the antibody blocks the collagen binding site of the I domain. An aspartate residue, from the CDR3 loop of the antibody heavy chain, coordinates the MIDAS metal ion in a manner similar to that of a glutamate residue from collagen. Substitution of the aspartate residue by alanine or arginine results in significant reduction of antibody binding affinity. Interestingly, although the mode of metal ion coordination resembles that of the open conformation, the I domain maintains an overall closed conformation previously observed only for unliganded I domains.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>1031-41</ArticlePages>
            <ArticleTitle>Crystal structure of the alpha1beta1 integrin I domain in complex with an antibody Fab fragment.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Karpusas</LastName>
                    <ForeName>Michael</ForeName>
                </Author>
                <Author>
                    <LastName>Ferrant</LastName>
                    <ForeName>Janine</ForeName>
                </Author>
                <Author>
                    <LastName>Weinreb</LastName>
                    <ForeName>Paul H</ForeName>
                </Author>
                <Author>
                    <LastName>Carmillo</LastName>
                    <ForeName>Amie</ForeName>
                </Author>
                <Author>
                    <LastName>Taylor</LastName>
                    <ForeName>Frederick R</ForeName>
                </Author>
                <Author>
                    <LastName>Garber</LastName>
                    <ForeName>Ellen A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142, USA. michael_karpusas@yahoo.com.</Affiliations>
            <ArticleChemicalList>Immunoglobulin Fab Fragments;Integrin alpha1beta1;Recombinant Fusion Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Crystallography, X-Ray; Humans; Immunoglobulin Fab Fragments; Integrin alpha1beta1(chemistry); Mutagenesis; Protein Conformation; Recombinant Fusion Proteins(chemistry)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>327</Volume>
                <Issue>5</Issue>
                <Title>Journal of molecular biology</Title>
                <Issn>0022-2836</Issn>
                <MedlineTa>J Mol Biol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>huAQC2 Fab epitope of α integrin I domain</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>D10, S12, S14, R78, Q79, T80, D113, H117, R147</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>1MHP_A</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10116</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figures 2,3 and PDB 1MHP</LocationOfData>
                <EpitopeId>102278</EpitopeId>
                <ReferenceRegion>D154, S156, S158, R222, Q223, T224, D257, H261, R291</ReferenceRegion>
                <EpitopeEvidenceCode>Author provided Identifier</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The source molecule is a chimeric I domain from the α 1 chain of rat Integrin VLA-1, where four residues that differ between the rat and human sequences were exchanged with the human Integrin counterparts to allow anti-human integrin antibody binding. These substitutions were G217V, R218Q, Q219R and L222R. The authors positions refer to the complete rat α1 integrin chain, as shown in the PDB entry [PDB: 1MHP].</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <BCellId>1631867</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>α1β1 integrin (VLA-1)</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P56199.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P05556.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 25 µg, first in CFA and boosts in IFA.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The generation of the AQC2-related class of monoclonal antibodies is described in Gotwals PJ et al. (1999) Biochemistry 38: 8280-88 [PMID: 10387073]. The heavy and light chains of the muAQC2 antibody were cloned.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The involvement of the Asp101 residue of the epitope-specific mAb in its interaction with the I domain of α1 integrin chain was tested with biotinylated WT antibody and competition with the mutant. The Asp101Arg or Asp101Ala mutants were able to bind the protein only in the absence of Mn2+.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>muAQC2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>1MHP_A</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10116</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 2, 3, 4, Table 1 and PDB 1MHP</LocationOfData>
                        <BCellId>964</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>α1β1 integrin (VLA-1)</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P56199.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P05556.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 25 µg, first in CFA and boosts in IFA.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The generation of the AQC2-related class of monoclonal antibodies is described in Gotwals PJ et al. (1999) Biochemistry 38: 8280-88 [PMID: 10387073]. The heavy and light chains of the muAQC2 antibody were cloned and then humanized using consensus human frameworks chosen following homology matching and the version with optimal α1β1 integrin binding properties was chosen as huAQC2. Antibody binds strongly to α1β1 integrin and sterically inhibits its interaction with collagen.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.8</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of huAQC2 Fab on a chimeric rat/human α1ß1 I domain was determined by molecular replacement from the crystal structure of the complex. The asymmetric unit of the crystal contains two identical antigen-Fab complexes. The chimeric rat/human α1ß1 I domain construct is composed of I domain from the α 1 chain of rat Integrin VLA-1, where four residues that differ between the rat and human sequences were exchanged with the human Integrin counterparts to allow anti-human integrin antibody binding. These substitutions were G217V, R218Q, Q219R and L222R.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>huAQC2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>huAQC2</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1MHP_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1MHP_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>1MHP_A</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10116</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1MHP</ComplexPdbId>
                            <AntibodyChain1PdbChain>X</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>Y</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>AB</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>Antigen-antibody contacts are not provided in the paper. Comparison with antibody-free α1β1 integrin I domain from rat [PDB: 1CK4] and human [PDB: 1QC5] indicates that there are only minor differences in integrin conformation due to huAQC5 Fab binding. Cofactor, the MIDAS metal ion, coordinates the antigen-antibody interaction by heavy chain antibody residue X: D101:H3 with antigen residues B: D154, S156, S158, T224, H261, D257.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>B: D154, S156, S158, R222, Q223, T224, D257, H261, R291</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>X: R31:H1, H56:H2, Y58:H2, D101:H3; Y: N30:L1, Y48:L2, N93:L3, W90:L3, W95:L3;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>B: S156, N157, S158, Y160, E192, Q218, R219, G220, G221, R222, Q223, T224, E259, H261, N263, Y264, Y289, R291, L294, ( MN)400</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>X: S30, R31, T33, W47, S52, G53, H56, Y58, F99, G100, D101; Y: V29, N30, Y48, L49, G67, Y70, W90, S91, N93, W95</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>1014.5</ContactAreaForAntigen>
                                <ContactAreaForAntibody>1026.7</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

